General, Pancreatic cancer, Colorectal cancer, Breast cancer, Non-small cell lung cancer (NSCLC)
other systemic therapies
The primary objective of this study is to:
Evaluate the safety and tolerability of AMG 305 in adult participants
Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose
Determine the recommended phase 2 dose (RP2D)
Evaluate the safety and tolerability of AMG 305 in adult participants , determine the optimal biologically active dose (OBD) that is at or below the maximum tolerated dose (MTD), where MTD 1 is the maximum tolerated starting dose and MTD 2 is the maximum tolerated target dose Determination of the recommended phase 2 dose (RP2D).
